Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

K Reich

Showing results (111-120 of 218) with videos related to

Pageof 22
Sort By:
Journal of the European Academy of Dermatology and Venereology : JEADV|September 11, 2018
Long-term safety profile of ixekizumab in patients with moderate-to-severe plaque psoriasis: an integrated analysis from 11 clinical trialsR G Langley, A B Kimball, H Nak, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|January 8, 2014
Secukinumab improves hand, foot and nail lesions in moderate-to-severe plaque psoriasis: subanalysis of a randomized, double-blind, placebo-controlled, regimen-finding phase 2 trialC Paul, K Reich, A B Gottlieb, et al.
The Journal of Infection|March 3, 2015
Severe ulcerative penile leishmaniasis--Importance of PCR-based diagnosticsV G Herbert, A Böer-Auer, A Brandenburg, et al.
Allergy|December 3, 2010
A new instrument for the assessment of patient-defined benefit in the treatment of allergic rhinitisN Franzke, I Schäfer, K Jost, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|January 11, 2011
Efficacy and safety of adalimumab in patients with psoriasis previously treated with anti-tumour necrosis factor agents: subanalysis of BELIEVEJ-P Ortonne, S Chimenti, K Reich, et al.
The British Journal of Dermatology|December 3, 1999
Graft-versus-host disease-like immunophenotype and apoptotic keratinocyte death in paraneoplastic pemphigusK Reich, U Brinck, M Letschert, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|May 12, 2019
Use of dose-exposure-response relationships in Phase 2 and Phase 3 guselkumab studies to optimize dose selection in psoriasisM Lebwohl, R G Langley, Y Zhu, et al.
The British Journal of Dermatology|August 4, 2019
A 24-week multicentre, randomized, open-label, parallel-group study comparing the efficacy and safety of ixekizumab vs. fumaric acid esters and methotrexate in patients with moderate-to-severe plaque psoriasis naive to systemic treatmentK Reich, M Augustin, D Thaçi, et al.
The British Journal of Dermatology|October 28, 2018
Effect of secukinumab on the clinical activity and disease burden of nail psoriasis: 32-week results from the randomized placebo-controlled TRANSFIGURE trialK Reich, J Sullivan, P Arenberger, et al.
Journal of Immunology (Baltimore, Md. : 1950)|November 21, 2001
Engagement of the Fc epsilon RI stimulates the production of IL-16 in Langerhans cell-like dendritic cellsK Reich, A Heine, S Hugo, et al.
Pageof 22

Showing results (111-120 of 218) with videos related to

Sort By:
Pageof 22
Journal of the European Academy of Dermatology and Venereology : JEADV|September 11, 2018
Long-term safety profile of ixekizumab in patients with moderate-to-severe plaque psoriasis: an integrated analysis from 11 clinical trialsR G Langley, A B Kimball, H Nak, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|January 8, 2014
Secukinumab improves hand, foot and nail lesions in moderate-to-severe plaque psoriasis: subanalysis of a randomized, double-blind, placebo-controlled, regimen-finding phase 2 trialC Paul, K Reich, A B Gottlieb, et al.
The Journal of Infection|March 3, 2015
Severe ulcerative penile leishmaniasis--Importance of PCR-based diagnosticsV G Herbert, A Böer-Auer, A Brandenburg, et al.
Allergy|December 3, 2010
A new instrument for the assessment of patient-defined benefit in the treatment of allergic rhinitisN Franzke, I Schäfer, K Jost, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|January 11, 2011
Efficacy and safety of adalimumab in patients with psoriasis previously treated with anti-tumour necrosis factor agents: subanalysis of BELIEVEJ-P Ortonne, S Chimenti, K Reich, et al.
The British Journal of Dermatology|December 3, 1999
Graft-versus-host disease-like immunophenotype and apoptotic keratinocyte death in paraneoplastic pemphigusK Reich, U Brinck, M Letschert, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|May 12, 2019
Use of dose-exposure-response relationships in Phase 2 and Phase 3 guselkumab studies to optimize dose selection in psoriasisM Lebwohl, R G Langley, Y Zhu, et al.
The British Journal of Dermatology|August 4, 2019
A 24-week multicentre, randomized, open-label, parallel-group study comparing the efficacy and safety of ixekizumab vs. fumaric acid esters and methotrexate in patients with moderate-to-severe plaque psoriasis naive to systemic treatmentK Reich, M Augustin, D Thaçi, et al.
The British Journal of Dermatology|October 28, 2018
Effect of secukinumab on the clinical activity and disease burden of nail psoriasis: 32-week results from the randomized placebo-controlled TRANSFIGURE trialK Reich, J Sullivan, P Arenberger, et al.
Journal of Immunology (Baltimore, Md. : 1950)|November 21, 2001
Engagement of the Fc epsilon RI stimulates the production of IL-16 in Langerhans cell-like dendritic cellsK Reich, A Heine, S Hugo, et al.
Pageof 22